Dapagliflozin (DAPA) Effects in HFpEF

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT04730947
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    10 mg orally once a day
  • Placebo — DRUG
    Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient

Study Details

The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.

Key Dates

Start date
Feb 24, 2021
Status verified
Sep 2023
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022

Study Design

Enrollment
38 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin Group
    Subjects with HFpEF will take the study drug dapagliflozin daily
  • Placebo Comparator: Placebo Group
    Subjects with HFpEF will take a placebo daily

Primary Outcome Measure

Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise [ Time Frame: Baseline, 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies